Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study

Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study

Abstract Background Epilepsy occurs in up to 90 % of all individuals with tuberous sclerosis complex (TSC). In 67 % disease onset is during childhood. In ≥ 50 % seizures are refractory to currently available treatment options. The mTOR-Inhibitor Everolimus (Votubia®) was approved for the treatment o...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Sharon Samueli, Klaus Abraham, Anastasia Dressler, Gudrun Gröppel, Angelika Mühlebner-Fahrngruber, Theresa Scholl, Gregor Kasprian, Franco Laccone, Martha Feucht
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: BMC 2016-11-01
Seri Bilgileri:Orphanet Journal of Rare Diseases
Konular:
Tuberous sclerosis complex
Epilepsy
Child
mTOR
Everolimus
Online Erişim:http://link.springer.com/article/10.1186/s13023-016-0530-z

Internet

http://link.springer.com/article/10.1186/s13023-016-0530-z

Benzer Materyaller